

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

~~BEST AVAILABLE COPY~~









Univ. of Min.
Bio-Medical
Library

06 06 94

JUNE 1994, VOLUME 34, NUMBER 6

NEUROSURGERY

OFFICIAL JOURNAL OF THE CONGRESS OF NEUROLOGICAL SURGEONS



Published by Williams & Wilkins

esters, polyalkylcyanoacrylates, polyamino acids, polyorthoesters, and others are possible candidates as biodegradable drug carriers. Among them, the polyanhydrides and the poly(α -hydroxyacid)s have attracted the most attention (46, 60). The first application of a controlled release polymeric system in the brain was aimed at improving the labeling of perivascular meningeal projections from cat trigeminal ganglia (50). Since this study, different research groups, such as Langer's group (Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA) have developed biocompatible polymeric systems permitting the controlled and localized release of neuroactive substances directly into the brain (42).

The first polymeric devices developed were macroscopic implants also called monolithic devices. Drugs are incorporated into polymers by triturating dry powdered drug with similarly treated polymer and pressing weighed aliquots of the mixture in a press (trituration method) or by dissolving both the polymer and the drug in a solvent, evaporating the solvent, and pressing the resulting material (solution method). These macroscopic implants have the shape of a nail, disk, wafer, or pipe. Many implants have been prepared and studied for drug delivery into the brain of antimitotic drugs (9, 19, 30, 39, 58, 69, 81), corticosteroids (59, 70), angiogenesis inhibitors (66, 68), nerve growth factor (33, 57, 79), and dopamine (5, 23, 28, 78). Furthermore, macroscopic polymeric devices have been used for the treatment of glioblastomas in humans. Oda et al. (54) reported the first clinical trials with Silastic implants loaded with 5-fluorouracil and were followed by Kubo et al. (41) who used other drugs. No definite conclusions have been drawn from these studies because of the heterogeneity of treated tumors. Recently, Brem and coworkers (11, 14) extensively studied the interstitial chemotherapy of malignant gliomas with carmustine-loaded polymer devices. A phase I-II trial was performed with carmustine-loaded polyanhydride systems (13), and a multicentric phase III clinical trial is being conducted by the same group.

LINKAGE OF TWO CONCEPTS: MICROENCAPSULATION AND STEREOTACTIC NEUROSURGERY

For several years, we have explored the potential applications of microencapsulation of therapeutic agents to provide controlled drug release in the CNS. Microparticles prepared by the classic microencapsulation methods usually range in size between 1 and 1000 μm (Fig. 1). Particles smaller than 1 μm are referred to as nanoparticles (38). Because of their size, these microparticles can be easily implanted by stereotaxy in discrete, precise, and functional areas of the brain without causing damage to the surrounding tissue (Fig. 2). This implantation avoids the inconvenient insertion of large implants by open surgery and can be repeated if required. For implantation, the microspheres can be injected in a suspension or as a powder




FIGURE 1. Scanning electron micrograph of PLAGA microspheres. The bar in the lower right corner represents 100 μm . The average sphere diameter is 27 μm .



FIGURE 2. Photomicrograph of a brain section from a rat with PLAGA microspheres implanted into the striatum 10 days before (immunoperoxidase with anti-GFAP antibody, original magnification $\times 25$).

with special needles. The size of these particles can be adapted to suit the target. Microspheres can be used for drug release in discrete regions of the brain. Nanospheres have been used for the retrograde labeling of neurons as they are taken up by fibers and transported back to the neuronal somata when they are injected into brain tissue (40). This property may be used for delivering drugs directly inside neural cells. Similarly, the uptake of nanospheres by astrocytes also has been observed in vitro (24).

MICROENCAPSULATION

The first research leading to the development of microencapsulation procedures was published by Bugenburg de Jong

and Kaas (10) in 1931 and dealt with the preparation of gelatin microcapsules by the coacervation process. In the late 1930s and 1940s, Green and co-workers from the National Cash Register Co., Dayton, Ohio, developed the gelatin coacervation process, which was covered by several patents to promote carbonless copy paper (71). Since then, many other coating materials, processes, and applications have been developed by the pharmaceutical industry. Other industries, such as the food, cosmetic, horticultural, paint, print, photographic, computer, fertilizers, adhesives, cleaning, and aerospace industries, have been concerned with microencapsulated products (18). At the same time, the plastics industry has been involved continuously in the production and evaluation of new polymers with a potential application in microencapsulation (55).

It is theoretically possible to microencapsulate all types of drugs and many processes for the preparation of micro- or nanoparticles have been reported in the literature (20):

- Physicochemical processes such as simple or complex coacervation for the preparation of microcapsules and also microspheres.
- Chemical processes such as interfacial polycondensation. This method requires two different bifunctional monomers; one is contained within the core material to be encapsulated (discontinuous phase), and the second is present in the continuous phase. The two monomers react at the interface of the dispersed droplets, causing polymerization and membrane formation.
- Mechanical processes, including pan coating, spray coating, and fluidized-bed coating.

Several different microparticle structures exist. There are two main types: the reservoir device and the matrix system. The reservoir device (microcapsules or nanocapsules) is a system in which the drug is confined to a cavity surrounded by a unique polymeric membrane. The matrix system (microspheres or nanospheres) is a system in which the drug is dispersed throughout the particle. The mechanisms of drug release are different, depending partly on the microparticle structure. In the reservoir device, the drug diffuses through a membrane. In the matrix system, the drug diffuses either through the polymeric mass or in the pores filled with water. If the polymer is biodegradable, a combination of diffusion and degradation phenomena regulates the release kinetics. Furthermore, it is possible to incorporate magnetite particles in the polymeric matrix for controlling the drug release by the application of an extracorporeal magnet (43).

COATING POLYMERS

A polymer is a compound made up from many molecular units assembled one to one, called monomers. When the polymer is composed of two different monomeric units, it is designated as a copolymer. Although many natural or synthetic polymers are available for the controlled release of drugs, only a few are suitable for the release of high molecular weight drugs. The first polymers used for making implantable devices were nonbiodegradable, such as polydimethylsiloxane (Silastic) or poly(ethylene-co-vinylacetate). Subsequently, other

polymers have been experimented with, such as the acrylic or the vinyl compounds. Actually, the biodegradable polymers have been developed primarily for the medical field for evident reasons. Among them, the polyanhydrides and the aliphatic polyesters have been extensively studied. Their degradation is caused by the cleavage of the ester bond by hydrolysis.

The polyanhydrides are nonmutagenic, noncytotoxic, and nonteratogenic (46, 47), and their biocompatibility and biodegradability into the brain have been demonstrated (12, 67). Despite clinical trials in cancerology (13), this class of polymers still has not obtained any Food and Drug Administration approval for current clinical use.

The aliphatic polyesters include poly(α -hydroxyacid), poly(β -hydroxyacid), and poly(ϵ -caprolactone). Poly(ϵ -caprolactone) is a very slow biodegradable polymer, which has been studied for the design of subdermal implants (56). We have shown that poly(ϵ -caprolactone) microspheres implanted into the rat brain were not degraded until 9 months elapsed and were well tolerated (Menei et al., submitted for publication). Poly(β -hydroxyacid)s are constituted mainly by poly(β -hydroxybutyric acid) and poly(β -malic acid) and are widely studied (26). The poly(α -hydroxyacid)s are constituted of lactic and/or glycolic acid units. When the two types of monomeric units are associated along the same chain, copolymers are generated, poly(lactide-co-glycolide) (PLGA) (Fig. 3). The degradation products of the copolymers are lactic and glycolic acids, which are natural metabolic products. The long history of the clinical use of these copolymers, particularly as surgical sutures, has demonstrated their excellent histocompatibility (27, 74). PLGA microspheres are currently used in clinical practice as subdermal implants for the controlled release of luteinizing hormone-releasing hormone analogs.

The physicochemical and degradation properties of PLGA depend on many parameters, such as the molar ratio of the two monomers in the polymer backbone and the molecular weight of the polymer. For instance, as the crystallinity of the material decreases or the glycolic unit content increases up to an optimal lactic acid/glycolic acid ratio of 50:50, the rate of degradation of the backbone increases. The biodegradation rate of the PLGA copolymers may vary from less than 1 month to





FIGURE 3. Structures of lactic acid (a), glycolic acid (b), and a copolymer (c). *n*, percentage of L-lactic units; *p*, percentage of D-lactic units; *q*, percentage of glycolic units.

a period of some years, depending on the polymer composition (63) and the size of the device (73). It can therefore be modified and adapted to suit clinical purposes. The PLAGA systems can be easily sterilized by γ -irradiation, despite the alteration of the polymer properties (63). We have established the brain compatibility of the PLAGA microspheres and studied their fate after stereotactic implantation in the rat brain (52). Current efforts in our laboratory are aimed at using this type of microsphere for drug delivery in the CNS.

APPLICATIONS OF SUSTAINED RELEASE OF DRUGS FROM MICROPARTICLES INTO THE CENTRAL NERVOUS SYSTEM

Neuro-oncology

The PLAGA microspheres can be loaded with antimitotic drugs, irrespective of their solubility profile. Hydrophilic drugs like 5-fluorouracil (8) as well as lipophilic ones like carmustine (Torres et al., submitted for publication) were successfully entrapped. 5-FU-loaded microspheres have been implanted in the brain of glioma-bearing rats and the mean of survival increased markedly (7). However, it is evident that future progress in neuro-oncology will come from the biotechnologies that generate very potent peptides and proteins. Microspheres will certainly allow the locally controlled release of cytokines for immunotherapy (53) and of new tumor-killing agents like tumor necrosis factor (80).

Neurodegenerative diseases

This field is the most exciting, and potential applications of the implantable microparticles can be expected. Neurotransmitters, neuromodulators, neurohormones, and trophic factors, which clearly play a substantial role in the activity and maintenance of the CNS are being discovered in increasing numbers. Delivery of such compounds to the brain will be a difficult problem to overcome with classic methods of drug administration. In addition, because of the complex chemoarchitecture of the CNS, drug delivery to a very restricted region of the brain is always required.

In some neurodegenerative diseases, there is a striking depletion of one or more neurotransmitters. Implanted microspheres carrying the appropriate pharmacological agent can restore neurotransmission. It is possible to attain functionally significant amounts of dopamine for a prolonged period of time by implantation of PLAGA microspheres loaded with this neurotransmitter into the rat striatum (49). Bethanechol (an acetylcholinesterase-resistant cholinomimetic), released by polyanhydride microspheres implanted into the hippocampus of rats having undergone a cholinergic denervation, reversed lesion-induced memory deficits (35).

More interesting is the sustained release of neurotrophic molecules. These molecules have a profound influence on developmental events such as naturally occurring cell death, differentiation and process outgrowth (32, 72), and could be used for treating degenerative neurological conditions and promoting neural regeneration. The best characterized trophic molecule, nerve growth factor, has a spectrum of effects on

peripheral and central neurons. This peptide molecule cannot cross the blood-brain barrier and therefore needs to be administered directly into the brain. Biologically active nerve growth factor can be released over a 4.5-week period in vitro and in the brain from PLAGA microspheres (15).

The monoganglioside GM1 is a glycolipid that stimulates the reparative processes occurring after a brain lesion. It can be released in rat brain from serum albumin microspheres (51).

Microencapsulation methods also allow the loading of various cells, bacteria, viruses, and yeasts. The capsules allow both normal biological functioning (passage of nutrients, neurotransmitters, and other cell products) and protection of the contents from immunorejection. Although the brain is thought to be an immunoprivileged site, immunorejection of allo- and xenografts may occur (76). Macro- and microencapsulation of cells with a selectively permeable membrane allow immunoisolation from the host.

Microencapsulations of different types of cells (in particular, pituitary cells) through interfacial adsorption, interfacial precipitation, or microemulsion polymerization have been reported (22).

Not far from the microencapsulation technology, the techniques of macroencapsulation permit loading cells into hollow fibers that are subsequently closed at both ends with a polymeric glue. Aebischer et al. (4) used this procedure to encapsulate dopamine-releasing cells—embryonic mesencephalon, adrenal chromaffin cells, and an immortalized cell line, PC12, derived from a rat pheochromocytoma (1, 3, 36, 37). The same authors have demonstrated the feasibility and survival of macroencapsulated neural tissue transplantations (2, 77, 78).

Other potential applications

Currently, many other drugs have been incorporated into PLAGA microspheres, for example, hormones and hormone agonists (6, 61), neuroleptics (64), antimitotic drugs (8, 62), local anaesthetics (75), anti-inflammatory drugs (21), and steroids (16). The incorporation of other neuroactive drugs is being studied extensively, and other applications of microspheres are being investigated regarding chronic pain, spasticity, epilepsy, and neurological infections.

CONCLUSIONS

Targeting of drugs in the CNS by implantation of biodegradable microspheres is feasible and offers numerous theoretical advantages. The potential applications of these biodegradable microspheres for neurological diseases are legion. However, once the cerebral target is identified and the neuroactive drug is synthesized, work still remains before micro-particle devices can be used therapeutically. For precise clinical purposes, the preparation, characterization, and evaluation of microparticle devices require some years in animal models.

ACKNOWLEDGMENT

The 1992 Leksell-Elékta prize was awarded to this research program.

Received, October 22, 1993.

Accepted, December 20, 1993.

Reprint requests: P. Menei, Service de Neurochirurgie, CHU d'Angers, 4 rue Larrey, 49033 Angers Cedex 01, France.

REFERENCES

- Aebischer P, Goddard P, Timpson R, Signore A, Beauregard-Young A, Rampone C: Polymer encapsulated PC12 cells transplanted in MPTP lesioned primates. *Soc Neur Abstr* 16:963, 1990.
- Aebischer P, Tresco PA, Winn SR, Greene LA, Jaeger CB: Long term cross-species brain transplantation of a polymer-encapsulated dopamine-secreting cell line. *Exp Neurol* 111:269-275, 1991.
- Aebischer P, Wahlberg L, Tresco PA, Winn SR: Macroencapsulation of dopamine-secreting cells by coextrusion with an organic polymer solution. *Biomaterials* 12:50-56, 1991.
- Aebischer P, Winn SR, Galletti PM: Transplantation of neural tissue in polymer capsules. *Brain Res* 448:364-368, 1988.
- Becker JB, Robinson TE, Barton P, Sintov A, Siden R, Levy RJ: Sustained behavioral recovery from unilateral nigrostriatal damage produced by the controlled release of dopamine from a silicone polymer pellet placed into the denervated striatum. *Brain Res* 508:60-64, 1990.
- Benoit JP, Courteille F, Thies C: A physicochemical study of the morphology of progesterone loaded poly(D,L-lactide) microspheres. *Int J Pharm* 29:95-102, 1986.
- Boisdron-Celle M, Menei P, Benoit JP: Preparation of biodegradable 5-fluorouracil-loaded microspheres and study of their anticancer activity on animal model of glioma. Presented at the 9th International Symposium on Microencapsulation, Ankara, Turkey, September 13-15, 1993.
- Boisdron-Celle M, Ruiz JM, Benoit JP: Preparation and characterization of 5-fluorouracil-loaded microspheres as biodegradable anticancer drug carriers. Presented at the 6th International Conference on Pharmaceutical Technology, Paris, France, June 2-4, 1992.
- Buahin KG, Judy KD, Hartke C, Domb AJ, Maniar M, Colvin QM, Brem H: Controlled release of 4-hydroperoxycyclophosphamide from the fatty acid dimer-sebacic acid copolymer. *Polym Adv Technol* (in press).
- Bungenburg de Jong HG, Kaas A: Kur kenntuis der komplexkoazervation, V. Mitteilung: Relative verschiebungen im elektrischen gleichstromfelde von flussigkeits-einschleibungen in komplexkoazervat-tropfehen. *Biochem Z* 232:338-345, 1931.
- Brem H: Polymers to treat brain tumors. *Biomaterials* 11:699-701, 1990.
- Brem H, Kader A, Epstein JL, Tamargo RJ, Domb A, Langer R, Leong K: Biocompatibility of bioerodible controlled release polymers in the rabbit brain. *Sel Cancer Ther* 5:55-65, 1989.
- Brem H, Mahaley MS, Vick NA, Black KL, Schold SC, Eller TW, Cozzens JW, Kenealy JN: Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. *J Neurosurg* 74:441-446, 1991.
- Brem H, Walter KA, Langer R: Polymers as controlled drug delivery devices for the treatment of malignant brain tumors. *Eur J Pharm Biopharm* 39:2-7, 1993.
- Camarata PJ, Suryanarayanan R, Turner DA, Parker RG, Ebner TJ: Sustained release of nerve growth factor from biodegradable polymer microspheres. *Neurosurgery* 30:313-319, 1992.
- Cavalier M, Benoit JP, Thies C: The formation and characterization of hydrocortisone-loaded poly((\pm))lactide) microspheres. *J Pharm Pharmacol* 38:249-253, 1986.
- Davis BK: Diffusion in polymer gel implants. *Proc Natl Acad Sci USA* 71:3120-3123, 1974.
- Deasy PB: Microencapsulation and related drug process, in Swarbrick J (ed): *Drugs and Pharmaceutical Sciences*. New York, M. Dekker Inc., 1984, vol 20. pp 361.
- Domb A, Bogdanský S, Olivi A, Judy K, Dureza C, Pinn ML, Colvin M, Brem H: Controlled release of water soluble and hydrolytically unstable anticancer drugs for polymeric implants. *Polym Reprints* 32:219-220, 1991.
- Donbrow M: *Microcapsules and Nanoparticles in Medicine and Pharmacy*. Boca Raton, CRC Press Inc., 1992.
- Dubernet C, Benoit JP, Puisieux F: Ibuprofen-loaded ethylcellulose microspheres: Mechanism involved in the growth of drug crystals on the particle surface. *Eur J Pharm Biopharm* 37:49-53, 1991.
- Dupuy B, Cadic C, Gin H, Baquay C, Dufy B, Ducassou D: Microencapsulation of isolated pituitary cells by polyacrylamide micro-latex coagulation on agarose beads. *Biomaterials* 12:493-496, 1991.
- During MJ, Freese A, Sabel BA, Saltzman WM, Deutch A, Roth RH, Langer R: Controlled release of dopamine from a polymeric brain implant: In vivo characterization. *Ann Neurol* 25:351-356, 1989.
- Emmett CJ, Lawrence JM, Seeley PJ: Visualization of migration of transplanted astrocytes using polystyrene microspheres. *Brain Res* 447:223-233, 1988.
- Folkman J, Long DM: The use of silicone rubber as a carrier for prolonged drug therapy. *J Surg Res* 4:139-142, 1964.
- Fournie P, Domurado D, Guerin P, Brau C, Vert M, Pontikis R: In vivo fate of repeat-unit-radiolabelled poly(β -malic acid), a potential drug carrier. *J Bioact Compat Polym* 7:113-129, 1992.
- Frazza EJ, Schmidt EE: A new absorbable suture. *J Biomed Mater Res* 5:43-58, 1971.
- Freese A, Sabel BA, Saltzman WM, During MJ, Langer R: Controlled release of dopamine from a polymeric brain implant. In vitro characterization. *Exp Neurol* 103:234-238, 1989.
- Gimbrone MA, Cotran RS Jr, Leapman SB, Folkman J: Tumor growth and neovascularization: An experimental model using the rabbit cornea. *J Natl Cancer Inst* 42:413-427, 1974.
- Grossman SA, Rienhard C, Colvin OM, Chasin M, Brundrett R, Tamargo RJ, Brem H: The intracerebral delivery of BCNU by surgically implanted biodegradable polymers. *J Neurosurg* 76:640-647, 1992.
- Harbaugh RE, Saunders RL, Reeder RF: Use of implantable pumps for central nervous system drug infusion to treat neurological disease. *Neurosurgery* 23:693-698, 1988.
- Hefti F, Knüsel B: Neurotrophic factors and neurodegenerative diseases, in Hefti F, Brachet P, Will B, Christen Y (eds): *Growth Factors and Alzheimer's Disease*. Berlin, Springer-Verlag, 1991, pp 1-14.
- Hoffman D, Wahlberg L, Aebischer P: NGF released from a polymer matrix prevents loss of ChAT expression in basal forebrain neurons following a fimbria-fornix lesion. *Exp Neurol* 110:39-44, 1990.
- Hollister LE: Site-specific drug delivery to CNS: Old and new. *Neurobiol Aging* 10:631-650, 1989.
- Howard MA, Gross A, Grady MS, Langer RS, Mathiowitz E, Winn R, Mayberg MR: Intracerebral drug delivery in rat with lesion-induced memory deficits. *J Neurosurg* 71:105-112, 1989.
- Jaeger CB, Aebischer P, Tresco PA, Winn SR, Greene LA: Growth of tumour cell lines in polymer capsules: Ultrastructure of encapsulated PC12 cells. *J Neurocytol* 21:469-480, 1992.
- Jaeger CB, Winn SR, Aebischer P, Greene LA: Long term maintenance of encapsulated PC12 cells in vitro and as brain implants. *Soc Neurosci Abstr* 14:1007, 1988.
- Julienne MC, Alonso MJ, Gomez Amozá JL, Benoit JP: Preparation of poly(D,L-lactide/glycolide) nanoparticles of controlled particle

- size distribution: Application of experimental designs. *Drug Dev Ind Pharm* 18:1063-1077, 1992.
39. Katakura R, Kuwahara K, Mori T: A newly devised tablet with prolonged release of bleomycin in brain tumors. *Neurochirurgia (Stuttgart)* [Suppl]:363, 1981.
 40. Katz LC, Burkhalter A, Dreyer WJ: Fluorescent latex microspheres as a retrograde neuronal marker for in vivo and in vitro studies of visual cortex. *Nature* 310:498-500, 1984.
 41. Kubo O, Himuro H, Inoue N, Tajika Y, Tajika T, Tohyama T, Skairi M, Yoshida M, Kaetsu I, Kitamura K: Treatment of malignant brain tumors with slowly releasing anticancer drug-polymer composites. *No Shinkei Geka* 14:1189-1195, 1986.
 42. Langer R: Polymer implants for drug delivery in the brain. *J Controlled Release* 16:53-60, 1991.
 43. Langer R, Brown LR, Edelman E: Controlled release and magnetically modulated release systems for macromolecules. *Methods Enzymol* 112:399-423, 1985.
 44. Langer R, Folkman J: Polymers for sustained release of proteins and other macromolecules. *Nature* 263:797-800, 1976.
 45. Langer R, Peppas NA: Present and future applications of biomaterials in controlled drug release. *Biomaterials* 2:201-214, 1981.
 46. Leong KW, Brott BC, Langer R: Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. *J Biomed Mater Res* 19:941-955, 1985.
 47. Leong KW, D'Amore P, Marletta M, Langer R: Bioerodible polyanhydrides as drug carrier matrices. II: Biocompatibility and chemical reactivity. *J Biomed Mater Res* 20:51-64, 1986.
 48. Lindvall O, Björklund A: Transplantation strategies in the treatment of Parkinson's disease: Experimental basis and clinical trials. *Acta Neurol Scand* 126:197-210, 1989.
 49. McRae-Degueurce A, Hjorth S, Dillon DL, Mason DW, Tice TR: Implantable microencapsulated dopamine (DA): A new approach for slow-release DA delivery into brain tissue. *Neurosci Lett* 92:303-309, 1988.
 50. Mayberg M, Langer R, Zervas N, Moskowitz M: Perivascular meningeal projections from cat trigeminal ganglia: Possible pathway for vascular headaches in man. *Science* 213:228-230, 1981.
 51. Maysinger D, Jalsenjak V, Stolnik S, Garofalo L, Cuello AC, Jalsenjak I: Microencapsulated monosialoganglioside GM1: Physical properties and in vivo effect. *J Microencapsul* 6:35-42, 1989.
 52. Menei P, Daniel V, Montero-Menei C, Brouillard M, Pouplard-Barthelaix A, Benoit JP: Biodegradation and brain tissue reaction to poly(D,L-lactide-co-glycolide) microspheres. *Biomaterials* 14:470-478, 1993.
 53. Merchant RE, Merchant LH, Cook SHS, Mc Vicar DW, Young HF: Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. *Neurosurgery* 23:725-732, 1988.
 54. Oda Y, Ochiai Y, Murata T, Murata T, Mori K, Tokuriki Y, Handa H, Kobayashi A, Hashi K, Kieler J: Treatment of brain tumors with anticancer pellet. Experimental and clinical study. *No Shinkei Geka* 10:375-381, 1982.
 55. Peppas NA, Langer RS: *Advances in Polymer Science*. Berlin, Springer Verlag, 1993.
 56. Pitt CG, Gratzl MM, Kimmel GL, Surles J, Schindler A: Aliphatic polyesters II. The degradation of poly (DL-lactide), poly (ϵ -caprolactone), and their copolymers in vivo. *Biomaterials* 2:215-220, 1981.
 57. Powell EM, Sobarzo MR, Saltzman WM: Controlled release of nerve growth factor from a polymeric implant. *Brain Res* 515:309-311, 1990.
 58. Rama B, Mendel T, Jansen J, Dingeldein E, Mennel HD: The intraneoplastic chemotherapy in a rat brain tumour model utilizing methotrexate-polymethylmethacrylate-pellets. *Acta Neurochir (Wien)* 87:70-75, 1987.
 59. Reinhard CS, Radamsky ML, Sltzman WM, Hilton J, Brem H: Polymeric controlled release of dexamethasone in normal rat brain. *J Controlled Release* 16:331-340, 1991.
 60. Rosen HB, Chang J, Wnek GE, Linhardt RJ, Langer R: Bioerodible polyanhydrides for controlled drug delivery. *Biomaterials* 4:131-133, 1983.
 61. Ruiz JM, Benoit JP: In vivo peptide release from poly(d,l-lactic acid-co-glycolic acid) copolymer 50/50 microspheres. *J Controlled Release* 16:177-186, 1991.
 62. Spenlehauer G, Veillard M, Benoit JP: Formation and characterization of cisplatin loaded poly(d,l-lactide) microspheres for chemoembolization. *J Pharm Sci* 75:750-755, 1986.
 63. Spenlehauer G, Vert M, Benoit JP, Boddaert A: In vitro and in vivo degradation of poly(D,L lactide:glycolide) type microspheres made by solvent evaporation method. *Biomaterials* 10:557-563, 1989.
 64. Suzuki K, Price JC: Microencapsulation and dissolution properties of neuroleptic in a biodegradable polymer, poly(d,l-lactide). *J Pharm Sci* 74:21-24, 1985.
 65. Tamargo RJ, Brem H: Drug delivery to the central nervous system: A review. *Neurosurgery Quarterly* 2:259-279, 1992.
 66. Tamargo RJ, Bok RA, Brem H: Angiogenesis inhibition by minocycline. *Cancer Res* 51:672-675, 1991.
 67. Tamargo RJ, Epstein JI, Reinhard CS, Chasin M, Brem H: Brain biocompatibility of a biodegradable controlled release polymer in rats. *J Biomed Mater Res* 23:253-266, 1989.
 68. Tamargo JR, Leong KW, Brem H: Growth inhibition of the 9L glioma using polymers to release heparin and cortisone acetate. *J Neurooncol* 9:131-138, 1990.
 69. Tamargo RJ, Myseros JS, Epstein JI, Yang MB, Chasin M, Brem H: Interstitial chemotherapy of the 9L gliosarcoma: Controlled release polymers for drug delivery in the brain. *Cancer Res* 53:329-333, 1993.
 70. Tamargo JR, Sills AK, Reinhard CS, Pinn ML, Long DM, Brem H: Interstitial delivery of dexamethasone in the brain for the reduction of peritumoral edema. *J Neurosurg* 74:956-961, 1991.
 71. Thies C: Microencapsulation, in *Encyclopedia of Polymer Science and Engineering*. New York, J. Wiley & Sons Inc., 1987, vol 9, pp 724-745.
 72. Unsicker K, Grothe C, Westermann R, Wewetzer K: Cytokines in neural regeneration. *Curr Opin Neurobiol* 2:671-678, 1992.
 73. Visscher GE, Pearson JE, Fong JW, Argentieri GJ, Robinson RL, Maulding HV: Effect of particle size on the in vitro and in vivo degradation rates of poly(DL-lactide-co-glycolide) microcapsules. *J Biomed Mater Res* 22:733-746, 1988.
 74. Visscher GE, Robinson RL, Maulding HV, Fong JW, Pearson JE, Argentieri GJ: Biodegradation of and tissue reaction to 50:50 poly (DL-lactique-co-glycolide) microcapsules. *J Biomed Mater Res* 19:349-365, 1985.
 75. Wakiyama N, Juni K, Nakano M: Preparation and evaluation in vitro of poly(lactic acid) microspheres containing local anaesthetics. *Chem Pharm Bull (Tokyo)* 11:3363-3368, 1981.
 76. Widner H, Brundin P: Immunological aspects of grafting in the mammalian central nervous system: A review and speculative synthesis. *Brain Res Rev* 13:287-324, 1988.
 77. Winn SR, Tresco PA, Zielinski B, Greene LA, Jaeger CB, Aebischer P: Behavioral recovery following intrastriatal implantation of microencapsulated PC12 cells. *Exp Neurol* 113:322-329, 1991.
 78. Winn SR, Wahlberg L, Tresco PA, Aebischer P: An encapsulated dopamine-releasing polymer alleviates experimental Parkinsonism in rats. *Exp Neurol* 105:244-250, 1989.

79. Yamamoto S, Yoshimine T, Fujita T, Kuroda R, Irie T, Fujioka K, Hayakawa T: Protective effect of NGF atelocollagen mini-pellet on the hippocampal delayed neuronal death in gerbils. *Neurosci Lett* 141:161-165, 1992.
80. Yamasaki T, Kikuchi H, Moritake K, Nagao S, Iwasaki K, Paine JT, Kagawa T, Namba Y: A morphological and ultrastructural investigation of normal mouse brain tissue after intra-cerebral injection of tumor necrosis factor. *J Neurosurg* 65:659-663, 1992.
81. Yang MB, Tamargo RJ, Brem H: Controlled delivery of 1,3-bis(2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate copolymer. *Cancer Res* 49:5103-5107, 1989.

COMMENTS

This article provides a prospective on some novel biological strategies to introduce therapeutic agents into the brain. The matter is an important one because the blood-brain barrier is altered in disease to a variable and often to an insufficient degree. Sometimes, it is not altered at all. Nonlipid soluble drugs and larger molecules, such as monoclonal antibodies, are excluded largely by the brain's specialized endothelium. So are gene constructs, cells, many objective bioactive peptides, and a growing host of interesting substances with therapeutic possibilities. If stereotactically delivered, biodegradable microspheres have great potential to be used to advantage in targeting treatment to specific brain regions. Although this work remains chiefly experimental, it is exciting and worth knowing about now. Menei and his colleagues have provided an accessible and well-referenced glimpse into the future.

Nicholas A. Vick
Evanston, Illinois

The authors present an overview of the role of polymeric drug delivery in the brain. In particular, they describe their ongoing work utilizing polylactide microspheres for delivering drugs for localized release. They postulate that the microspheres would be particularly well suited for stereotactic implantation and retreatment when necessary.

The modeling of drug distribution in combination with precise stereotactic implantation potentially will allow for precise "drug" planning—similar to the approach taken for stereotactic radiation dosimetry planning.

The choice of polymer will depend on the application; for example, polycarboxyphenoxy propane anhydride with sebacic acid (which is clinically utilized) is ideal for releasing small lipid soluble compounds (1, 7). However, the fatty acid dimer polyanhydride has been shown to be superior for long-term release of water soluble agents such as carboplatin or 4-Hydroxyperoxycyclophosphamide (3). Polylactide polymers have different release characteristics and will therefore have a specific niche as well in the polymer-drug delivery armamentarium.

Although, ideally, the polymer should biodegrade with the release of the drug, there is no evidence that nonbiodegradable polymers necessarily have to be removed if there is no evidence of a short- or long-term deleterious effect. In fact, in general, nonbiodegradable polymers such as ethylene vinyl acetate copolymer poly(ethylene-co-vinyl acetate) are less reactive because they are simply inert implants. A potential drawback of the nonbiodegradable polymers is the desirability of not having any foreign material to serve as a possible nidus of infection. There is, however, a strong precedent for the neurosurgical use of nondegradable implants such as the silicone utilized in shunts.

We agree strongly that stereotactic implantation of a polymer with drugs greatly expands the ability to treat neurological disease selectively. On a simpler level, the polymer implants that have been extensively utilized in animal studies in the rat brain are easily inserted through a stereotactic trocar, for example, chemotherapeutic agents (2, 9), steroids (5, 10), anti-angiogenesis agents (6, 8), and immunotoxins (4).

Henry Brem
Baltimore, Maryland

1. Brem H: Polymers to treat brain tumors. *Biomaterials* 11:699-701, 1990.
2. Brem H, Walter KA, Langer R: Polymers as controlled drug delivery devices for the treatment of malignant brain tumors. *Eur J Pharm Biopharm* 39:2-7, 1993.
3. Domb A, Bogdansky S, Olivi A, Judy K, Dureza C, Lenartz D, Pinn ML, Colvin OM, Brem H: Controlled delivery of water soluble and hydrolytically unstable anti-cancer drugs for polymeric implants. *Polymer Reprints* 32:219-220, 1991.
4. Phillips PC, Levow C, Catterall M, Colvin OM, Pastan I, Brem H: Transforming growth factor α -pseudomonas exotoxin fusion protein (TGF α -PE38) treatment of subcutaneous and intracranial human medulloblastoma and glioma xenografts in athymic mice. *Cancer Res* 1994 (in press).
5. Reinhard CS, Radomsky M, Saltzman M, Brem H: Polymeric controlled release of dexamethasone in normal rat brain. *J Controlled Release* 16:331-340, 1991.
6. Tamargo R, Bok RA, Brem H: Angiogenesis inhibition by minocycline. *Cancer Res* 51:672-675, 1991.
7. Tamargo RJ, Brem H: Drug delivery to the central nervous system: A review. *Neurosurgery Quarterly* 2:259-279, 1992.
8. Tamargo RJ, Leong KW, Brem H: Growth inhibition of the 9L glioma using polymers to release heparin and cortisone acetate. *J Neurooncol* 9:131-139, 1990.
9. Tamargo RJ, Myseros JS, Epstein JI, Yang MB, Chasin M, Brem H: Interstitial chemotherapy of the 9L gliosarcoma: Controlled release polymers for drug delivery in the brain. *Cancer Res* 53:329-333, 1993.
10. Tamargo RJ, Sills AK, Reinhard CS, Pinn ML, Long DM, Brem H: Interstitial delivery of dexamethasone in the brain for the reduction of peritumoral edema. *J Neurosurg* 74:956-961, 1991.